{"id":13037,"date":"2025-07-16T01:45:21","date_gmt":"2025-07-16T01:45:21","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/13037\/"},"modified":"2025-07-16T01:45:21","modified_gmt":"2025-07-16T01:45:21","slug":"myriad-genetics-earns-2025-great-place-to-work","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/13037\/","title":{"rendered":"Myriad Genetics Earns 2025 Great Place To Work"},"content":{"rendered":"

SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.<\/a>, (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has received the Great Place to Work Certification for the third year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said Myriad Genetics is a Great Place To Work \u2013 30 percentage points higher than the average U.S. company.<\/p>\n

\u201cOur focus on inclusivity and caring makes this a great place to work,\u201d shared a current Myriad Genetics employee in the survey. \u201cOur employee resource groups give employees a place to connect with employees like them, an opportunity to share their struggles and successes, and a community to support them.\u201d<\/p>\n

Great Place To Work\u00ae is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation.<\/p>\n

\u201cAt Myriad Genetics, our teammates are critical to achieving our shared mission of advancing health and well-being for all,\u201d said Shereen Solaiman, chief people officer, Myriad Genetics. \u201cWe are honored to be recognized as a Great Place to Work for the third year in a row. This certification reflects the passion and dedication of our teammates, who are committed to building a workplace where every teammate feels connected, supported, and empowered to make a difference.\u201d<\/p>\n

“Great Place To Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience,” says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of employees regarding their company culture. \u201cBy successfully earning this recognition, it is evident that Myriad Genetics stands out as one of the top companies to work for, providing a great workplace environment for its employees.”<\/p>\n

Visit our careers page<\/a> to explore open roles and learn more about what it\u2019s like to work at Myriad. <\/p>\n

About Great Place to Work Certification\u2122
Great Place To Work\u00ae Certification\u2122 is the most definitive \u201cemployer-of-choice\u201d recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience \u2013 specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified.<\/p>\n

About Great Place To Work\u00ae
As the global authority on workplace culture, Great Place To Work\u00ae brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All\u2122 Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified\u2122 or receiving recognition on a coveted Best Workplaces\u2122 List.<\/p>\n

Learn more at greatplacetowork.com<\/a> and follow Great Place To Work on LinkedIn<\/a>, Twitter<\/a>, Facebook<\/a> and Instagram<\/a>.<\/p>\n

About Myriad Genetics\u00a0
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com<\/a>.<\/p>\n

Safe Harbor Statement
This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Myriad\u2019s commitment to building a workplace where every teammate feels connected, supported, and empowered to make a difference. These \u201cforward-looking statements\u201d are management\u2019s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company\u2019s filings with the U.S. Securities and Exchange Commission, including the company\u2019s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company\u2019s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.\u00a0<\/p>\n

Investor Contact\u00a0
Matt Scalo\u00a0
(801) 584-3532\u00a0
IR@myriad.com<\/a>\u00a0<\/p>\n

Media Contact\u00a0
Kate Schraml
(224) 875-4493
PR@myriad.com<\/a>\u00a0\u00a0<\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular…\n","protected":false},"author":2,"featured_media":13038,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[200,12723,851,12722,12721,79],"class_list":{"0":"post-13037","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-great-place-to-work","10":"tag-inc","11":"tag-myriad-genetics","12":"tag-nasdaqmygn","13":"tag-science"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/13037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=13037"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/13037\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/13038"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=13037"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=13037"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=13037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}